There have been a large number of studies on the development of novel drugs and treatment methods to improve glycolipid metabolism and then to relieve liver steatosis, liver fibrosis, insulin resistance, etc. Deletion of enzyme dihydroceramide desaturase 1, which disturbs ceramide double bond, could improve insulin resistance and hepatic steatosis (10). The gene discussed is DEGS1; the disease is fatty liver disease.